| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Fargesin targets multiple signaling pathways involved in inflammation and allergic responses. The compound exhibits anti-inflammatory activity by modulating cytokine production and inhibiting inflammatory mediators. Fargesin also shows anti-allergic effects by inhibiting mast cell degranulation and histamine release. The compound's neuroprotective effects may be mediated through antioxidant and anti-inflammatory mechanisms.
|
|---|---|
| ln Vitro |
Fargesin inhibits the PKC pathway, which includes nuclear factor AP-1, JNK downstream, and NF-̸B, to produce anti-inflammatory actions in THP-1 cells [3]. By lowering oxidative stress and apoptosis, fargesin, a putative β1-adrenergic receptor antagonist, shields the rat heart against ischemia/reperfusion injury [4].
In vitro, fargesin demonstrates anti-inflammatory activity by reducing the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) in activated immune cells. The compound inhibits mast cell degranulation and histamine release, contributing to its anti-allergic effects. Fargesin also exhibits antioxidant activity by scavenging free radicals and reducing oxidative stress in cell-based assays. |
| ln Vivo |
By preventing oxidative stress and encouraging the generation of NO, fargesin has antihypertensive effects on 2K1C hypertensive rats [1].
In vivo, fargesin has demonstrated anti-inflammatory and anti-allergic effects in animal models. The compound reduces inflammation in models of acute and chronic inflammation. Fargesin also shows neuroprotective effects in models of neurodegenerative diseases. The compound's diverse pharmacological activities suggest potential therapeutic applications in inflammatory, allergic, and neurodegenerative disorders. |
| Enzyme Assay |
Non-cellular enzyme assays for fargesin involve assessing its antioxidant activity using DPPH, ABTS, or FRAP radical scavenging assays. The compound's anti-inflammatory activity can be assessed using enzyme inhibition assays for COX-1/COX-2 or lipoxygenase. Binding studies can be performed using surface plasmon resonance or isothermal titration calorimetry to characterize interactions with specific targets.
|
| Cell Assay |
In vitro cellular assays for fargesin involve treating immune cells (e.g., macrophages, mast cells) or neuronal cells with the compound and assessing inflammatory and allergic responses. Cytokine production is measured by ELISA. Mast cell degranulation is assessed by measuring β-hexosaminidase release. Oxidative stress is measured using fluorescent probes such as DCFH-DA. Cell viability is assessed using MTT or CellTiter-Glo® assays.
|
| Animal Protocol |
In vivo animal experiments with fargesin are conducted in rodent models of inflammation, allergy, and neurodegeneration. Mice or rats are treated with fargesin via oral or intraperitoneal administration. Inflammatory models include carrageenan-induced paw edema and LPS-induced systemic inflammation. Allergic models include ovalbumin-induced allergic airway inflammation. Neuroprotective effects are assessed in models of oxidative stress or neurodegeneration.
|
| ADME/Pharmacokinetics |
Fargesin has a molecular weight of 370.40 and a molecular formula of C₂₁H₂₂O₆. It is a solid at room temperature with a purity of ≥98%. The compound is soluble in DMSO and other organic solvents. It is typically stored at -20°C, protected from light and moisture. The compound is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Fargesin is a research compound for laboratory use only and is not intended for human therapeutic use. In preclinical studies, it has been generally well-tolerated at therapeutic doses. Standard laboratory safety precautions should be followed when handling the compound. It may cause skin, eye, and respiratory irritation.
|
| References |
|
| Additional Infomation |
It has been reported that plants of the genus Aristolochia, plants of the genus Piper, and other organisms with available data contain (+/-)-falgixin.
Fargesin (CAS 31008-19-2) is a naturally occurring lignan with anti-inflammatory, anti-allergic, and neuroprotective properties. It modulates cytokine production, inhibits mast cell degranulation, and exhibits antioxidant activity. The compound is available from various commercial suppliers for research applications. |
| Molecular Formula |
C21H22O6
|
|---|---|
| Molecular Weight |
370.3958
|
| Exact Mass |
370.141
|
| CAS # |
31008-19-2
|
| PubChem CID |
10926754
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
506.4±50.0 °C at 760 mmHg
|
| Melting Point |
132.0 to 136.0 °C
|
| Flash Point |
208.9±30.0 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.580
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
515
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
COC1=C(C=C(C=C1)[C@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC5=C(C=C4)OCO5)OC
|
| InChi Key |
AWOGQCSIVCQXBT-LATRNWQMSA-N
|
| InChi Code |
InChI=1S/C21H22O6/c1-22-16-5-3-12(7-18(16)23-2)20-14-9-25-21(15(14)10-24-20)13-4-6-17-19(8-13)27-11-26-17/h3-8,14-15,20-21H,9-11H2,1-2H3/t14-,15-,20-,21+/m0/s1
|
| Chemical Name |
5-[(3S,3aR,6R,6aR)-6-(3,4-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-1,3-benzodioxole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~337.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6998 mL | 13.4989 mL | 26.9978 mL | |
| 5 mM | 0.5400 mL | 2.6998 mL | 5.3996 mL | |
| 10 mM | 0.2700 mL | 1.3499 mL | 2.6998 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
